Compare Accenture plc (ACN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Accenture plc vs GeneDx Holdings Corp — how do they compare? Accenture plc trades at $181 (market cap $110.24B), while GeneDx Holdings Corp trades at $82.2 (market cap $2.45B). The key difference: Accenture plc is far larger — about 45× GeneDx Holdings Corp's market cap, and Accenture plc pays a 3.62% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| ACN | WGS | |
|---|---|---|
Market Cap | $110.24B | $2.45B |
Sector | Technology | Technology |
52-Week High | $288.54 | $167.51 |
52-Week Low | $124.41 | $34.51 |
Enterprise Value | $108.45B | $2.49B |
Dividend Yield | 3.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $179.82, up 0.88% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 EPS of $3.80, beating estimates, and maintains solid fundamentals with a P/E of 14.36 and net margin of 10.66%. Recent partnerships with TEPCO and AlphaSense highlight its AI-driven growth initiatives, while cash flow from operations surged to $11.47B in 2025.
The outlook remains positive given consistent earnings beats and strategic AI investments, though risks include competitive pressures and market volatility. Analyst consensus is bullish with a $189.77 price target, suggesting upside potential. Investors should weigh robust cash generation against elevated valuation multiples and macroeconomic headwinds.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
